Innova Captab Ltd
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]
- Market Cap ₹ 4,591 Cr.
- Current Price ₹ 802
- High / Low ₹ 1,260 / 662
- Stock P/E 52.5
- Book Value ₹ 142
- Dividend Yield 0.00 %
- ROCE 11.6 %
- ROE 11.6 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|
373 | 411 | 785 | 859 | 865 | 958 | 1,018 | |
322 | 356 | 687 | 760 | 755 | 836 | 890 | |
Operating Profit | 51 | 54 | 99 | 99 | 110 | 122 | 129 |
OPM % | 14% | 13% | 13% | 11% | 13% | 13% | 13% |
1 | 1 | 3 | 9 | 9 | 17 | 16 | |
Interest | 5 | 4 | 5 | 18 | 14 | 2 | 5 |
Depreciation | 10 | 6 | 7 | 11 | 11 | 17 | 23 |
Profit before tax | 38 | 46 | 89 | 78 | 94 | 120 | 117 |
Tax % | 26% | 26% | 25% | 26% | 27% | 25% | |
28 | 34 | 66 | 58 | 68 | 89 | 87 | |
EPS in Rs | 232.42 | 287.50 | 551.50 | 11.99 | 11.91 | 15.63 | 15.28 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 7% |
TTM: | 17% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 26% |
3 Years: | 11% |
TTM: | 16% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 17% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 17% |
3 Years: | 14% |
Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Equity Capital | 12 | 12 | 12 | 48 | 57 | 57 |
Reserves | 98 | 133 | 199 | 220 | 666 | 756 |
54 | 45 | 176 | 237 | 244 | 329 | |
81 | 178 | 157 | 173 | 187 | 223 | |
Total Liabilities | 245 | 368 | 544 | 678 | 1,155 | 1,365 |
73 | 79 | 161 | 161 | 164 | 637 | |
CWIP | 0 | 7 | 0 | 22 | 339 | 21 |
Investments | 0 | 0 | 60 | 60 | 60 | 60 |
172 | 282 | 322 | 435 | 593 | 647 | |
Total Assets | 245 | 368 | 544 | 678 | 1,155 | 1,365 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
31 | 42 | 58 | 39 | 112 | 20 | |
-6 | -20 | -188 | -88 | -472 | -100 | |
-23 | -19 | 125 | 51 | 368 | 84 | |
Net Cash Flow | 1 | 3 | -5 | 3 | 8 | 4 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Debtor Days | 85 | 123 | 81 | 98 | 92 | 95 |
Inventory Days | 84 | 107 | 63 | 67 | 68 | 94 |
Days Payable | 92 | 132 | 84 | 102 | 111 | 119 |
Cash Conversion Cycle | 77 | 99 | 60 | 63 | 49 | 70 |
Working Capital Days | 45 | 39 | 23 | 44 | 58 | 65 |
ROCE % | 28% | 33% | 21% | 15% | 12% |
Documents
Announcements
- Recommendation Of GMP Compliance Certificate By The State Service Of Ukraine On Medicines And Drugs Control. 2d
-
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015.
16 Oct - SCN (15-Oct-2025) demands ₹15,81,37,255.40 for excess ITC (May 2020–Mar 2024); company to respond.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Oct - SEBI Reg 74(5) certificate (07-Oct-2025): no demat/remat requests for quarter ended 30-Sep-2025.
-
Closure of Trading Window
26 Sep - Trading window closed Oct 1, 2025 until 48 hours after unaudited results for quarter/half-year ended Sept 30, 2025.
-
Pursuant To Regulation 30 Read With Part A Of Schedule III Of SEBI (LODR) Regulations, 2015 ('SEBI Listing Regulations'), We Hereby Inform You That M/S. CARE Ratings Limited, A Credit Rating Agency, Has Revised The Credit Ratings On Banking Facilities Of The Company
16 Sep - CARE reaffirms CARE A/A1; long-term ₹389.38 crore (enhanced); outlook revised to Positive on Sept 16, 2025.
Concalls
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
Business Profile[1]
Innova Captab Limited is an integrated pharmaceutical player with a strong presence across the pharmaceutical value chain